Objective: To evaluate the effect of tamsulosin, 0.4 mg once daily, on sexual function in comparison with placebo and alfuzosin, 2.5 mg three times daily, in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO). Methods: Data from 830 patients randomized into three European multicenter studies with similar protocols were analyzed. In two studies, patients were randomized to receive either tamsulosin, 0.4 mg once daily, or placebo, and in the third, patients were randomized to receive either a fixed dose of tamsulosin, 0.4 mg once daily, or alfuzosin, titrated to 2.5 mg three times daily. The studies employed a 2-week placebo run-in period, followed by a 12-week study period. Sexual function was assessed by related adverse events and by a sexual function score determined from a life-style questionnaire. Results: Abnormal ejaculation occurred significantly more frequently in patients treated with tamsulosin than in those receiving placebo (p = 0.045); however, the incidence of abnormal ejaculation was similar in patients receiving tamsulosin or alfuzosin in the comparative study. Abnormal ejaculation was not perceived as a major problem by the patients since it resulted in few treatment discontinuations (n = 3). It was also reversible on drug withdrawal. There was no difference between tamsulosin and placebo or alfuzosin with regard to the occurrence of decreased libido or impotence. In addition, there was no significant difference in the change in sexual function score between patients treated with tamsulosin and those treated with alfuzosin. Compared with patients receiving placebo, there was, however, a significant improvement in total sexual function score in patients receiving tamsulosin (p = 0.042). Conclusions: Tamsulosin, 0.4 mg once daily, is well tolerated and has no overall negative impact on sexual function compared with placebo or alfuzosin. Compared with placebo, tamsulosin may even improve sexual function.

Keywords:
Lower urinary tract symptoms, Benign prostatic obstruction, α1A-Adrenoceptor antagonist, Sexual function, Tamsulosin
1.
Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474–479.
2.
Garraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469–471.
3.
Abrams P: Managing lower urinary tract symptoms in older men. BMJ 1995;310:1113–1117.
4.
Caine M: Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990;17:641–649.
5.
Chapple CR: α-Adrenergic blocking drugs in bladder outflow obstruction: What potential has α1-adrenoceptor selectivity? Br J Urol 1995;76(suppl 1):47–55.
6.
Kunisawa Y, Kawabe K, Niijima T, Honda K, Takenaka T: A pharmacological study of alpha-adrenergic receptor subtypes in smooth muscle of human urinary bladder and prostatic urethra. J Urol 1985;134:396–398.
7.
Yamada S, Tanaka C, Kimura R, Kawabe K: Alpha-1-adrenoceptors in human prostate: Characterization and binding characteristics of alpha-1-antagonists. Life Sci 1994;54:1845–1854.
8.
Chapple CR, Christmas TJ, Milroy EJG: A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction. Urol Int 1990;45(suppl 1):47–55.
9.
Wilde MI, Fitton A, Sorkin EM: Terazosin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in benign prostatic hyperplasia. Drugs Ageing 1993;3:258–277.
10.
Wilde MI, Fitton A, McTavish D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in benign prostatic hyperplasia. Drugs 1993;45:410–429.
11.
Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DF, Padley RJ, for the HYCAT investigator group: The Hytrin Community Assessment Trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996;47:159–168.
12.
Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533–539.
13.
Fulton B, Wagstaff AJ, Sorkin EM: Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995;49:295–320.
14.
Chapple CR: Selective α1-adrenoceptor antagonists in benign prostatic hyperplasia: Rationale and clinical experience. Eur Urol 1996;29:129–144.
15.
Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AFGVM, Abrams P, on behalf of the European Tamsulosin Study Group: Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996;29:155–167.
16.
Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G: Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995;288:201–207.
17.
Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA: Pharmacology of tamsulosin: Saturation-binding isotherms and competition analysis using cloned α1-adrenergic receptor subtypes. Prostate 1997;33:55–59.
18.
Michel MC, Grübbel B, Taguchi K, Verfürth F, Otto T, Kröpfl D: Drugs for treatment of benign prostatic hyperplasia: Affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 1996;16:21–28.
19.
Abrams P, Schulman CC, Vaage S, and the European Tamsulosin Study Group: Tamsulosin, a selective α1C-adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic obstruction (symptomatic BPH). Br J Urol 1995;76:325–336.
20.
Lepor H, and the Tamsulosin Investigator Group: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892–900.
21.
Schulman CC, Cortvriend J, Jonas U, Lock TMTW, Vaage S, Speakman MJ: Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist: Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996;29:145–154.
22.
Lepor H, and the Tamsulosin Investigator Group: Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial. Urology 1998;51:901–906.
23.
Lepor H, and the Tamsulosin Investigator Group: Tamsulosin, long-term, open-label, extension study to evaluate response and efficacy (abstract 1293). J Urol 1997;157(suppl 4):331.
24.
Schulman CC, Lock TMTW, Buzelin JM: Tamsulosin: 3-year follow-up of efficacy and safety in 516 patients with LUTS suggestive of BPO (abstract 983). J Urol 1998;159(suppl 5):256.
25.
Wilde MI, McTavish D: Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs 1996;52:883–898.
26.
Lukacs B, Comet D, Doublet J-M, Thibault P: Effect of age and symptom severity on patients’ perceived sexuality in French men with symptomatic benign prostatic hypertrophy (BPH) (abstract 160). Eur Urol 1996;30(suppl 2):56.
27.
Mebust WK, Ackerman R, Barry MJ, Batista J, Bosch R, Boyle P, et al: Symptoms evaluation, quality of life and sexuality; in Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, et al (eds): Proc 3rd Int Consultation on Benign Prostatic Hyperplasia (BPH), Monaco, 1995. SCI, 1996, pp 255–296.
28.
Puente JG, Sweeney M, Cary MM, Roehrborn CG, for the PREDICT Investigators: Relationship between age, lower urinary tract symptoms (LUTS) and various domains of erectile dysfunction (ED) in 1098 patients in the PREDICT Study (abstract 1272). J Urol 1998;159(suppl 5):331.
29.
Roehrborn CG: The newly established guidelines for the diagnosis and management of benign prostatic hyperplasia. Curr Opin Urol 1995;5:30–34.
30.
Peters DH, Sorkin EM: Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993;46:177–208.
31.
Kedia KR, Persky L: Effect of phenoxybenzamine (dibenzyline) on sexual function in man. Urology 1981;18:620–622.
32.
Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL: Relative importance of sexuality and quality of life in patients with prostatic symptoms: Results of an international study. Eur Urol 1997;31:272–280.
33.
Buzelin JM, Fonteyne E, Kontturi M, Witjes WPJ, Khan A: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997;80:597–605.
34.
Boyarsky S, Jones G, Paulson DF, Prout GR: A new look at bladder neck obstruction by the Food and Drug Administration regulators: Guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg 1977;68:29–31.
35.
Guthrie RM, Siegel RL: Effect of doxazosin therapy on symptoms of benign prostatic hyperplasia and sexual function in hypertensive patients (abstract 850). Br J Urol 1997;80(suppl 2):217.
36.
Lukacs B, Leplège A, Thibault P, Jardin A: Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996;48:731–740.
37.
Andersson K-E, Stief CG: Neurotransmission and the contraction and relaxation of penile erectile tissues. World J Urol 1997;15:14–20.
38.
Price DT, Schwinn DA, Kim JH, Carson CC, Caron MG, Lefkowitz RJ: Alpha1 adrenergic receptor subtypes mRNA expression in human corpus cavernosum (abstract 287). J Urol 1993;149(suppl 4):285A.
39.
Traish AM, Netsuwan N, Daley J, Padman-Nathan H, Goldstein I, Saenz de Tejada I: A heterogeneous population of α1-adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine. J Urol 1995;153:222–227.
40.
Becker AJ, Stief CG, Machtens S, Schultheiss D, Hartmann U, Truss MC, Jonas U: Oral phentolamine as treatment for erectile dysfunction. J Urol 1998;159:1214–1216.
41.
Walden PD, Durkin MM, Lepor H, Wetzel JM, Gluchowski C, Gustafson EL: Localization of mRNA and receptor subtype binding sites for the alpha 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J Urol 1997;157:1032–1038.
42.
Furukawa K, Rosario DJ, Smith DJ, Chapple CR, Uchiyama T, Chess-Williams R: Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens. Br J Pharmacol 1995;116:1605–1610.
43.
Moriyama N, Nasu K, Takeuchi T, Akiyama K, Murata S, Nishimatsu H, Yano J, Tsujimoto G, Kawabe K: Quantification and distribution of α1-adrenoceptor subtype mRNAs in human vas deferens: Comparison with those of epididymal and pelvic portions. Br J Pharmacol 1997;122:1009–1014.
44.
Lee E, Lee C: Clinical comparison of selective and non-selective α1A-adrenoceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997;80:606–611.
45.
Chapple CR, Baert L, Thind P, Höfner K, Khoe GS, Spångberg A, on behalf of the European Tamsulosin Study Group: Tamsulosin 0.4 mg once daily: Tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). Eur Urol 1997;32:462–470.
46.
Schou J, Holm NR, Meyhoff HH: Sexual function in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1996;30:119–122.
47.
Emberton M, Neal DE, Black N, Fordham M, Harrison M, McBrien MP, Williams RE, McPherson K, Devlin HB: The effect of prostatectomy on symptom severity and quality of life. Br J Urol 1996;77:233–247.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.